Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries.

Autor:	Pereira FMT; Hospital São Camilo, Pompeia, São Paulo, Brazil.; Latin American Cooperative Oncology Group-Genitourinary, Porto Alegre, Brazil., Silva AGE; Instituto de Câncer e Transplante de Curitiba, Curitiba, Brazil., Dettino ALA; A.C. Camargo Cancer Center, São Paulo, Brazil., Cardoso APG; Latin American Cooperative Oncology Group-Genitourinary, Porto Alegre, Brazil.; Hospital Israelita Albert Einstein, São Paulo, Brazil., Sasse AD; Grupo Sasse de Oncologia e Hematologia, Campinas, Brazil., Kann AG; Latin American Cooperative Oncology Group-Genitourinary, Porto Alegre, Brazil.; Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.; Centro Paulista de Oncologia-Oncoclínicas, São Paulo, Brazil., Dzik C; Hospital São Camilo, Pompeia, São Paulo, Brazil.; Latin American Cooperative Oncology Group-Genitourinary, Porto Alegre, Brazil., Herchenhorn D; Latin American Cooperative Oncology Group-Genitourinary, Porto Alegre, Brazil.; Grupo d'Or de Oncologia, Rio de Janeiro, Brazil., Jardim DLF; Hospital Sírio Libanês, São Paulo, Brazil., Lopera D; Oncologos de Occidente, Manizales, Colombia., Ayadi M; Salah Azaiz Institute, Tunis, Tunisia.; Faculté de médecine, Tunis, Tunisia., Salman P; Fundación Arturo López Pérez, Santiago, Chile., Kopp RAM; Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia., De Carvalho RS; Benefícência Portuguesa de São Paulo, São Paulo, Brazil., Cavallero SRA; Centro de Tratamento Oncológico, Belém, Brazil., Aguiar S; Universidad de la República, Montevideo, Uruguay., Souza VC; Latin American Cooperative Oncology Group-Genitourinary, Porto Alegre, Brazil.; Grupo d'Or de Oncologia, Bahia, Brazil., Uson Junior PLS; Mayo Clinic, Phoenix, AZ., Soares A; Latin American Cooperative Oncology Group-Genitourinary, Porto Alegre, Brazil.; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Centro Paulista de Oncologia-Oncoclínicas, São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	JCO global oncology [JCO Glob Oncol] 2021 Apr; Vol. 7, pp. 545-549.
DOI:	10.1200/GO.20.00507
Abstrakt:	Purpose: To present a summary of the recommendations for the treatment and follow-up for the biochemical recurrence of castration-resistant prostate cancer (PCa) as acquired through a questionnaire administered at the Prostate Cancer Consensus Conference for Developing Countries. Methods: A total of 27 questions were identified as relating to this topic. Responses from the clinician were tallied and are presented in percentage format. Topics included the use of imaging in staging, treatment recommendations across different patient scenarios of life expectancy and prostate-specific antigen (PSA) doubling time, and follow-up for nonmetastatic castration-resistant PCa. Results: A consensus agreed that in optimal conditions, positron emission tomography-computed tomography with prostate-specific membrane antigen would be used although in limited resource situations the combined use of CT of the abdomen and pelvic (or pelvic MRI), a bone scan, and a CT of the thorax or chest x-ray was recommended. In cases when PSA levels double in < 10 months, more than 90% of clinicians agreed on the use of apalutamide or enzalutamide, regardless of life expectancy. With a doubling time of more than 10 months, > 54% of experts recommended no treatment independent of life expectancy. More than half of the experts, regardless of resources, recommended follow-up with a physical examination and PSA levels every 3-6 months and imaging only in the case of symptoms. Conclusion: The voting results and recommendations presented in this document can be used by physicians to support management for biochemical recurrence of castration-resistant PCa in areas of limited resources. Individual clinical decision making should be supported by available data. Competing Interests: Felipe Moraes Toledo PereiraHonoraria: Janssen, Zodiac Pharma, MSD, Libbs, Bayer, AmgenConsulting or Advisory Role: Janssen Adriano Gonçalves e SilvaHonoraria: MSD Oncology, Janssen Oncology, Astellas Pharma, Roche, Pfizer/EMD Serono, Bayer, Bristol-Myers Squibb BrazilConsulting or Advisory Role: Janssen Oncology, Astellas Pharma, Pfizer/EMD Serono, MSD OncologyResearch Funding: MSD Oncology, Janssen OncologyTravel, Accommodations, Expenses: Janssen Oncology, Astellas Pharma, MSD Oncology, Roche Aldo Lourenço Abbade DettinoHonoraria: Janssen-Cilag, Bayer, Astellas Pharma, RocheConsulting or Advisory Role: NovartisResearch Funding: Janssen, RocheTravel, Accommodations, Expenses: MSD Oncology Ana Paula Garcia CardosoConsulting or Advisory Role: Janssen Oncology, Pfizer, Astellas PharmaSpeakers' Bureau: Janssen Oncology, Novartis, MSD Oncology, Astellas Pharma, AstraZeneca, BayerTravel, Accommodations, Expenses: Ipsen, Janssen Oncology, Bristol-Myers Squibb Andre Deeke SasseHonoraria: Roche, Astellas Pharma, Janssen-Cilag, Bristol-Myers Squibb, Merck KGaA, MSD Oncology, NovartisConsulting or Advisory Role: Astellas Pharma, Janssen-Cilag, Merck KGaA, Novartis, RocheResearch Funding: Bristol-Myers SquibbTravel, Accommodations, Expenses: MSD Oncology, Janssen-Cilag Ariel Galapo KannConsulting or Advisory Role: Janssen OncologySpeakers' Bureau: Janssen Oncology, GlaxoSmithKline, Roche Carlos DzikConsulting or Advisory Role: Janssen-Cilag, IPSEN, NovartisSpeakers' Bureau: Janssen OncologyTravel, Accommodations, Expenses: Astellas Pharma, Janssen Oncology Daniel HerchenhornConsulting or Advisory Role: Janssen-Cilag Denis Leonardo Fontes JardimHonoraria: Janssen-Cilag, Roche/Genentech, Astellas Pharma, MSD Oncology, Bristol-Myers Squibb Brazil, Pfizer, Libbs, MerckConsulting or Advisory Role: Janssen-Cilag, Pfizer, MSDTravel, Accommodations, Expenses: MSD, Bristol-Myers Squibb Brazil, Janssen-Cilag Diego LoperaConsulting or Advisory Role: Bristol-Myers Squibb, Pfizer, NovartisSpeakers' Bureau: Dr Reddy's Laboratories, Bristol-Myers Squibb, Boehringer Ingelheim, PfizerTravel, Accommodations, Expenses: MSD Oncology Pamela SalmanConsulting or Advisory Role: Roche/Genentech, Novartis, Lilly, Merck SeronoSpeakers' Bureau: Roche/Genentech, Novartis, Lilly Ray Antonio Manneh KoppHonoraria: Astellas Scientific and Medical Affairs Inc, Janssen-Cilag, Bayer, Merck Sharp & Dohme, Roche, Bristol-Myers Squibb, Sanofi, AstraZeneca, PfizerConsulting or Advisory Role: Astellas Pharma, Janssen-Cilag, Roche, Merck Serono, Merck Sharp & Dohme, AstraZeneca, Sanofi, PfizerSpeakers' Bureau: San Jorge Foundation, ACHOResearch Funding: Pfizer, Merck Sharp & Dohme, NovartisTravel, Accommodations, Expenses: Merck Sharp & Dohme Sandro Roberto De Araujo CavalleroHonoraria: Pfizer, Astellas Pharma, Janssen Oncology, AstraZenecaConsulting or Advisory Role: Janssen Oncology, MSD Oncology, Astellas PharmaSpeakers' Bureau: Pfizer, Janssen-Cilag, Astellas PharmaTravel, Accommodations, Expenses: Pfizer, Roche/Genentech, Janssen-Cilag, Astellas Pharma Vinicius Carrera SouzaConsulting or Advisory Role: Janssen, Astellas Pharma, Bayer, Bristol-Myers Squibb BrazilResearch Funding: JanssenTravel, Accommodations, Expenses: Janssen Andrey SoaresHonoraria: Janssen, Pfizer, Bayer, Novartis, AstraZeneca, Astellas Pharma, Pierre Fabre, Merck Serono, Sanofi, Roche, MSDConsulting or Advisory Role: Astellas Pharma, Janssen, Roche, Bayer, Lilly, AstraZeneca, Novartis, MSD, Bristol-Myers SquibbResearch Funding: Bristol-Myers SquibbTravel, Accommodations, Expenses: AstraZeneca, Pfizer, Astellas Pharma, Bristol-Myers Squibb, Bayer, Roche, Janssen, Merck Serono, Sanofi, Ipsen, MSDNo other potential conflicts of interest were reported.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu